Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

A Phase 1 Dose Escalation and Expanded Cohort Study of PF-06821497 in the treatment of adult patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC

Sub-indication: Miscellaneous Malignancies

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Pfizer

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.